Cite

    Mohammed, T. et al. (2020). Hypothesis validation of rosiglitazone a potential inhibitor against glycogen synthase kinase-3β, for the management of multifaceted pathophysiology of the diabetic wound: An insilico study. Medical hypotheses. p. . [Online].